Trial Profile
Phase II Study to Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Apr 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 29 Jun 2020 Status changed from active, no longer recruiting to completed.
- 19 Aug 2019 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
- 19 Aug 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.